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A phase 2, open-label, Investigator-initiated study to evaluate the safety and
efficacy of Apremilast in subjects with recalcitrant contact or Atopic dermatitis
E.M. Volf1, S. Au MD2, N. Dumont2, A.B. Gottlieb1,2 1Tufts University School of Medicine, 2Tufts
Medical Center
Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are chronic inflammatory diseases
characterized by pruritis and erythematous plaques that become lichenified over time. Current
systemic treatments are associated with numerous end-organ toxicities. Apremilast is a novel
phosphodiesterase type IV inhibitor which has been shown to decrease TNF-a, IFN-g, IL-2, IL-8,
IL-12, IL-17, IL-20, IL-23, leukotrienes, and iNOS in human cell lines. Phase 2 studies
demonstrated efficacy in patients with psoriasis or psoriatic arthritis. This therapy may offer
improved control over AD and ACD. The primary objective is to evaluate the efficacy and safety
of Apremilast in patients with recalcitrant moderate to severe atopic or contact dermatitis. This
study is a proof-of-concept, phase 2, open-label, single institution trial to evaluate the efficacy,
safety, and tolerability of Apremilast, 20mg capsule twice daily for twelve weeks, in ten subjects.
Clinical efficacy was determined by the Eczema Assessment Severity Index (EASI) and the
Investigator Global Assessment (IGA). Preliminary results show that half of the patients
experienced a 30% or greater improvement in EASI scores during the treatment phase. Half of
the subjects also demonstrated a one point improvement in IGA from baseline. Overall, there was
a 5% worsening in mean EASI scores in all eight subjects. In two subjects who completed
treatment, one experienced a 32% improvement in EASI score and a one-point improvement in
IGA. Two patients in treatment phase experienced a 46 and 56% improvement in EASI at week 8
and week 10, respectively. Both patients had a one point improvement in IGA. The two patients
who withdrew consent had a 10 and 20% worsening in EASI with no change in IGA at week 2. All
patients tolerated Apremilast well with no serious adverse events or withdrawal due to side
effects. Common side effects included headache, dermatitis flare, and mild GI distress (nausea,
dyspepsia, soft stool). Small study with low power. Single arm with no control. Early results of this
ongoing trial demonstrate that Apremilast is well-tolerated in subjects with 50% showing mild
improvement in their dermatitis during the 12-week treatment course. However, the efficacy was
modest and not as good as that seen in patients with moderate to severe psoriasis.
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CRetrospective and prospective analysis of cutaneous chemotherapy REACTions
at Washington University (CCT REACT study)
P. Wu, M. Anadkat, Washington University in Saint Louis
The cutaneous reactions to new targeted monoclonal antibodies and multi-kinase inhibitors occur
commonly, cause significant patient discomfort, and can lead to attenuation or premature
discontinuation of therapy. As yet, there are no standardized treatments or large studies on the
phenomena. We retrospectively and prospectively analyzed patients with targeted chemother-
apy-associated cutaneous reactions at our institution to better understand its natural history, and
we describe our interim results here. Subjects were recruited from the dermatology service for
medication-related skin changes, as well as oncology clinics prior to or following initiation of
targeted chemotherapy. Gender, age, ethnicity, type of targeted chemotherapy, treatment for skin
symptoms were noted; answers to standardized questions on smoking status, sunscreen use, type
and stage of cancer, other chemotherapy medications and cutaneous symptoms were recorded.
Affected areas were noted in the chart and standardized photographs were taken. A total of 66
patients have been enrolled thus far with a male to female ratio of 1.6 to 1. The most commonly
used chemotherapy agents were cetuximab and erlotinib in our group. Patients were seen an
average of 2.4 visits for skin changes but were followed for longer with medical records. The most
common cutaneous reaction was the papulopustular eruption on the trunk seen in 68% of cases.
Other skin findings were predominant eczematous symptoms in 15% of cases, trichomegaly in
6%, nail changes (onycholysis) in 4% and in 6% of patients there were no skin findings. In one
case a patient developed an erosive pustular alopecia while on erlotinib, which had only
previously been reported with gemfitinib. One hundred percent of patients were give a
prescription for a topical cortisone. Minocycline was our first line oral agent 76% of the time,
followed by doxycycline (13%). The oral medication was changed in 20% of cases, usually due to
lack of efficacy. In 16% of cases the medication was changed to an oral retinoid either acitretin or
isotretinoin with good clinical outcome. Skin changes were reported as reasons to alter the dose
or discontinue a targeted chemotherapy regimen in 19% of cases. More study will need to be
done to address the timing of skin therapy administration as well as recommendations for a
treatment ladder.
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Revisiting low dose total skin electron beam therapy in the management of
Mycosis fungoides
C. Harrison1, J. Young1, D. Navi1, N. Riaz2, R. Hoppe2, Y. Kim1 1Departments of Dermatology
and 2Radiation Oncology, Stanford University School of Medicine, Stanford, CA
Total skin electron beam therapy (TSEBT) is a highly effective treatment for Mycosis fungoides
(MF). The standard course consists of 36Gy delivered over an 8–10 week period. This regimen is
time intensive and associated with significant treatment related toxicities including erythema,
desquamation, anhydrosis, alopecia, and chronic xerosis. The aim of this study is to perform a
retrospective review of patients receiving low dose TSEBT in an attempt to identify a lower dose
alternative while retaining a favorable efficacy profile. We identified 102 patients with mycosis
fungoides who received low dose TSEBT (5–25Gy) at the Department of Radiation Oncology from
1958 to 1995. Only patients with T2–T4 MF receiving a first dose of TSEBT were included. Those
with extracutaneous disease or evidence of lymph node involvement were excluded. Patients
were subdivided into cohorts ranging from 5 to 10Gy,410–20Gy, and420–25Gy. Of the initial
102 patients, 36 received an additional course of low dose TSEBT upon documentation of relapse.
Results of the additional course were analyzed as a separate cohort. Primary efficacy endpoints
were overall response (OR), overall survival (OS), and progression free survival (PFS). OR rates
(450% improvement) were 88% among T2-T4 patients receiving 5–10Gy (n¼ 25). In
comparison, OR was 98% among T2–T4 patients in the 410–20Gy cohort (n¼47). OR did
not differ significantly between the 410–20Gy and 420–25Gy subgroups (98 vs 100%
respectively). Median overall survival (OS) across all initial low dose cohorts was 8.5 years (T2),
2.2 years (T3), and 7.6 years (T4). When analyzed by dose category, median PFS was 2.08 years
(5–10Gy), 6.04 years (10–20Gy), and 5.41 years (20–25Gy). In the additional dose cohort
(n¼ 36), median time to the additional TSEBT course was 9 months. OR was greater than 95%
across all three radiation subgroups (5–25Gy). We identified410–20Gy to be an optimal TSEBT
dose with high OR rates in addition to favorable OS and PFS measurements. This has served as the
foundation for a current prospective study examining the efficacy and side effect profile of 12Gy
TSEBT in patients with MF.
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Investigation of cell therapy for generalized severe recessive dystrophic
Epidermolysis bullosa by intradermal allogeneic fibroblasts randomized against
placebo injections
S.S. Venugopal1,8, W.F. Yan1,8, K. Tran2, M. Sturm3, J. Fogarty3, J. Nelson4, J.W. Frew1,8,
W. Melbourne2, L.M. Rhodes1 F. Wood5, P. Marinkovic6, S. Igawa7, A. Ishida-Yamamoto7,
D. F. Murrell1,8 1Deparment of Dermatology, St George Hospital, Sydney, Australia; 2Department
of Anatomical Pathology, St George Hospital, Sydne,y Australia; 3Cell and Tissue Therapies WA,
Royal Perth Hospital, Perth, Australia; 4Department of Pharmacy, St George Hospital, Sydney,
Australia; 5McComb Foundation, Perth, Australia; 6Department of Dermatology, Stanford
University, USA; 7Asahikawa Medical College, Asahikawa, Japan; 8University of New South
Wales, Sydney, Australia
This is the first double blind placebo-controlled randomized controlled trial of intradermal
cultured allogeneic fibroblast injections compared with intradermal injections of placebo
transport solution alone in severe generalised RDEB. Intradermal injection of cultured fibroblasts
has been shown to increase collagen VII expression in unblistered skin of RDEB-GS patients even
at 3 months, yet the cultured fibroblasts had disappeared by 2 weeks (1). We designed a single
institution, double blinded, intra-patient, placebo-controlled randomized controlled trial to
determine the clinical response of intradermal cultured allogeneic fibroblast injections, from a
healthy male donor, in chronic erosions of patients with RDEB-GS and compare this with
transport solution alone Five patients each with up to 6 pairs of symmetrical wounds were
biopsied and randomly injected at baseline with the two treatment arms and monitored over 12
months. Subject and Investigator Visual Analogue Scores (VAS) for appearance, pain and pruritus,
Quality of Life in Epidermolysis Bullosa (QOLEB) (2) and non-invasive testing of epidermal fluid
content studies were performed. Skin biopsies were performed to determine type-VII collagen
expression, electron microscopy ultrastructure, presence of inflammatory markers and fluorescent
insitu hybridzization (FISH). Indirect immunofluorescence for anti-type VII collagen antibodies,
HLA typing and reverse transcriptase polymerase chain reaction (RT-PCR) to detect COL7A1
expression were performed. We will present the 12 month clinical and histopathological results
for 5 patients. The methods used provide a feasible new therapy for RDEB patients.
www.jidonline.org 1953
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The development of a disease-specific quality of life instrument for autoimmune
Bullous diseases - The ABQOL
A. Hanna1, D. Sebaratnam1, S. Chee1, S.S. Venugopal1, L. Rhodes1, B. Welsh2, D.F. Murrell1,3
1Department of Dermatology, St George Hospital, Sydney, Australia; 2Sunbury Private Consulting
Suites, Melbourne, Australia; 3University of New South Wales, Sydney, Australia
The literature puts forward that disease-specific instruments are the most specific tools available
in this domain, as they are most sensitive to changes in disease status. At present, no disease-
specific instrument exists for use in autoimmune bullous disease (AIBD). Non-structured
interviews and focus groups were conducted with 26 patients suffering AIBD for item generation
and validation. Eighty-eight items were combined and reduced to form a pilot QOL in
autoimmune bullous disease (ABQOL) questionnaire with 45 questions, which was distributed to
73 AIBD patients across Australia, along with the Dermatology Life Quality Index (DLQI). Bullous
experts were then consulted in an attempt to further refine the 45- questions before factor analysis
was completed. Statistical analysis was then performed to assess the utility of the pilot ABQOL.
Item performance features such as item difficulty, response distribution, item-test and item-rest
correlation were performed on each question after first stratifying each item under three
subscales—‘‘symptom’’, ‘‘function’’ or ‘‘emotion’’. Content validity and discriminant validity
were also assessed and test-retest studies were also conducted. Internal consistency was assessed
by calculating Cronbach alpha values for each subscale. Face and content validity were
established by conducting in-depth, open interviews with bullous patients as well as through
review of the pilot ABQOL questionnaire by experts in bullous disease. Discriminative validity
has been assessed qualitatively by reviewing the number of insensitive items in the pilot ABQOL
(15/45 [33%]) compared to the DLQI (8/10 [80%]), through which the pilot ABQOL was found to
be superior to the DLQI. No items were considered difficult, and response distribution was
considered optimal for most questions. Cronbach alpha coefficients were found to be above 0.70
for each of the three subscales, and thus questionnaire reliability was considered optimal. Further
work is being done to refine the number of questions in the ABQOL-questionnaire. A condensed
version of the ABQOL will be ready by March.
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Quality of life in Cutaneous Lupus Erythematosus
R Klein1,2, S Moghadam-Kia1,2, J LoMonico1,2, K Chilek1,2, E Gaines1,2, J Okawa1,2, C Coley1,
L Taylor 1, MM Chren3, V Werth1,2 1Phil VAMC, 2University of Pennsylvania, 3UCSF
The purpose of this study was to assess the relationship between CLE and quality of life (QOL).
We specifically sought to compare QOL in CLE to other diseases and to determine which
independent variables are associated with poor QOL. All patients with CLE or SLE were invited to
participate in the study. Subjects were asked to complete the Skindex-29, which assesses QOL in
terms of symptoms, emotions, and functioning, with higher scores indicating worse QOL. Disease
severity was assessed with the Cutaneous Lupus Erythematosus Disease Area and Severity Index
(CLASI). Mean Skindex-29 scores in CLE were compared to norms for other diseases. Mean scores
within the CLE population were compared between different genders, ethnicities, and disease
subtypes. Pearson’s correlation coefficients were calculated for Skindex-29 scores and disease
severity, age, and age at diagnosis. 157 subjects were included in the analysis. Overall, patients
with lupus were most affected in the emotions domain (m¼ 48, SD¼ 28) relative to symptoms
(m¼40, SD¼ 23) and functioning (m¼ 28, SD¼25). The subscales were highly intercorrelated,
such that a high score in one tended to be associated with high scores in the others (Pearson’s r
range 0.65–0.78, all Po0.0001). Compared to 8 other diseases, QOL in lupus was significantly
impaired across all three domains; with respect to symptoms, only vulvodynia (m¼ 50, SD¼ 17)
and eczema (m¼ 48, SD¼23) had higher scores than CLE (all Po0.0001). In the emotions
domain, lupus was comparable to dermatomyositis (mean¼ 45, SD¼27) and vulvodynia
(m¼50, SD¼ 20), and the other diseases were all less affected (all Po0.0009). For functioning,
only patients with vulvodynia (m¼ 44, SD¼ 22) were more impaired than patients with lupus
(Po0.0001). Female gender was associated with poor quality of life in all three domains (all
Po0.006). There was a correlation between increased disease severity and worse QOL across all
three subscales (Pearson’s r range 0.27–0.38, all Po0.0006). There was a small correlation
between younger age and worse symptoms and emotions scores (all Po0.04). There was also a
small correlation between younger age at diagnosis and worse symptoms scores (P¼ 0.04).CLE
has a profoundly negative impact on QOL, particularly in women and individuals with severe
disease.
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